Overview of Clorazepate Dipotassium
Clorazepate Dipotassium, identified by the National Drug Code (NDC) 51672-4043, is a benzodiazepine medication used for the treatment of anxiety, insomnia, and certain types of seizures. Here is a detailed analysis of its market and price projections.
Product Details
- Generic Name: Clorazepate Dipotassium
- Proprietary Name: Clorazepate Dipotassium
- Dosage Form: Tablet
- Route of Administration: Oral
- Labeler Name: Taro Pharmaceuticals U.S.A., Inc.[1]
Market Trends
Drug Price Inflation
The pharmaceutical market is experiencing a rise in drug prices, with a projected increase of 3.8% in 2024, driven partly by specialty pharmaceuticals. While this trend is more pronounced in specialty drugs, it can have a ripple effect across the entire pharmaceutical market, including generic and branded drugs like Clorazepate Dipotassium[2].
Competition from Generics and Biosimilars
The life sciences industry is facing significant competition from generic drugs and biosimilars. This competition can impact the pricing and market share of branded and generic medications. For Clorazepate Dipotassium, being a generic drug, it may benefit from the increasing acceptance and utilization of generics, but it must also contend with the pricing pressures that come with this competition[3].
Pricing and Access
Current Pricing
As of the latest available data, the pricing for Clorazepate Dipotassium can vary based on the vendor, quantity, and other market factors. However, specific price data for NDC 51672-4043 is not readily available in the public domain. Generally, prices for generic medications like Clorazepate Dipotassium tend to be lower than their branded counterparts but can fluctuate based on market dynamics.
Price Projections
Given the overall trend of drug price inflation, it is likely that the price of Clorazepate Dipotassium will see some increase, although it may be more modest compared to specialty pharmaceuticals. Here are some key factors influencing price projections:
- Generic Drug Pricing: Prices for generic drugs tend to be stable or see minimal increases compared to branded drugs. However, with the increasing competition and regulatory pressures, there could be slight price adjustments[3].
- Market Demand: The demand for benzodiazepines, while not as high as for some specialty drugs, remains consistent due to their use in treating various conditions. This demand can help stabilize prices.
- Supply Chain: Any disruptions in the supply chain can lead to temporary price increases. However, companies like Taro Pharmaceuticals, which have established supply chains, are better positioned to manage such risks[1].
Regulatory and Market Environment
DEA Schedule and Regulatory Impact
Clorazepate Dipotassium is classified as a Schedule IV controlled substance, which means it has a lower potential for abuse compared to Schedule III substances but still requires careful monitoring. Regulatory changes or stricter enforcement of controlled substance regulations could impact its availability and pricing[1].
Patent and Exclusivity
Since Clorazepate Dipotassium is a generic medication, it is not subject to the same patent and exclusivity issues as branded drugs. However, the broader pharmaceutical landscape, including the patent cliff and the loss of exclusivity for high-revenue products, can influence the overall market dynamics and pricing strategies[3].
Industry Insights and Expert Opinions
Digital Transformation and Innovation
The life sciences industry is undergoing significant transformation driven by digital advancements and scientific innovations. While these innovations are more relevant to specialty and novel therapies, they can also impact the efficiency and cost structure of generic drug manufacturers, potentially influencing pricing[3].
Physician and Patient Perspectives
Physicians and patients are increasingly looking for cost-effective treatments without compromising on efficacy. The preference for generic medications like Clorazepate Dipotassium is likely to continue, driven by their lower cost and proven therapeutic benefits.
"Managing pharmacy expenditures and strengthening the supply chain is more important than ever," said Carina Dolan, associate vice president, clinical oncology, pharmacoeconomics and market insights, Vizient[2].
Key Takeaways
- Market Stability: The market for Clorazepate Dipotassium is expected to remain relatively stable, with minimal price increases due to its generic status.
- Competition: The drug will continue to face competition from other generic benzodiazepines and potentially from new therapeutic alternatives.
- Regulatory Environment: The DEA Schedule IV classification and any changes in regulatory policies could impact its pricing and availability.
- Industry Trends: The broader pharmaceutical market trends, including digital transformation and the rise of specialty drugs, may have indirect effects on the pricing and market dynamics of generic medications.
FAQs
What is Clorazepate Dipotassium used for?
Clorazepate Dipotassium is used for the treatment of anxiety, insomnia, and certain types of seizures.
Who manufactures Clorazepate Dipotassium with the NDC 51672-4043?
Taro Pharmaceuticals U.S.A., Inc. manufactures Clorazepate Dipotassium with the NDC 51672-4043[1].
What is the DEA Schedule classification for Clorazepate Dipotassium?
Clorazepate Dipotassium is classified as a Schedule IV controlled substance[1].
How does the rise of specialty pharmaceuticals affect the pricing of generic drugs like Clorazepate Dipotassium?
The rise of specialty pharmaceuticals can lead to overall drug price inflation, but the impact on generic drugs is typically less pronounced. However, it can still contribute to a modest increase in prices due to broader market dynamics[2].
What are the key factors influencing the price projections for Clorazepate Dipotassium?
Key factors include generic drug pricing trends, market demand, supply chain stability, and regulatory environment[1][3].
Sources
- FDA.report: NDC 51672-4043 Oral Tablet Clorazepate Dipotassium.
- Vizient Inc.: Vizient Projects 3.8% Drug Price Increase Driven by Specialty Pharmaceuticals.
- Deloitte Insights: 2025 life sciences outlook.
Last updated: 2025-01-03
